The prospects for a one-time treatment that reduces the risk of heart disease for the rest of a person’s life just got ...

Verve Therapeutics said Monday that initial data show that its investigational gene-editing therapy lowered cholesterol ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

The Boston-based company said its gene-editing treatment for people with high cholesterol was well-tolerated with no serious ...

Investigators from Mass General Brigham and Beth Israel Deaconess Medical Center have developed STITCHR, a new gene editing ...

CRISPR gene-editing technology offers curative potential for genetic diseases. The gene-editing market is projected to reach $30.8 billion by 2032. Top gene-editing pioneers include Intellia ...